<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35751632</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-5949</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>CNS neuroscience &amp; therapeutics</Title><ISOAbbreviation>CNS Neurosci Ther</ISOAbbreviation></Journal><ArticleTitle>Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients.</ArticleTitle><Pagination><StartPage>1532</StartPage><EndPage>1538</EndPage><MedlinePgn>1532-1538</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cns.13894</ELocationID><Abstract><AbstractText Label="BACKGROUND">Little is known about the influence of Riluzole on serum neurofilament light chain (sNfL) levels, a biomarker of prognosis in amyotrophic lateral sclerosis (ALS), and variations with time of sNfL concentrations are controversial.</AbstractText><AbstractText Label="METHODS">Sera from ALS patients (n&#xa0;=&#x2009;141) and controls (n&#xa0;=&#x2009;33) were collected at inclusion (sNfL1) and second visit (sNfL2, mean delay 10.4&#x2009;&#xb1;&#x2009;8.7&#xa0;months). sNfL levels, determined by single-molecule array, were compared between ALS and controls at both time points. sNfL concentration changes were compared between patients with Riluzole (w/Ril) at inclusion in the study and those who were treated by Riluzole following inclusion (w/o Ril). The factors influencing sNfL concentrations and changes were studied using linear regression and multivariate analysis.</AbstractText><AbstractText Label="RESULTS">sNfL levels were higher in ALS patients than in controls at the two time points (p&#x2009;&lt;&#x2009;0.00001). In ALS patients, sNfL concentrations were higher in females for both sNfL1 (p&#xa0;=&#xa0;0.014) and sNfL2 (p&#x2009;&lt;&#x2009;0.001). In the whole ALS group, sNfL levels were higher at sNfL2 than at sNfL1 (p&#x2009;&lt;&#x2009;0.001). sNfL1 and sNfL2 concentrations were similar between the two ALS subgroups (w/ and w/o Ril). ALS functional rating scale-revised rate of decline and gender were the two main factors significantly influencing both sNfL1 and sNfL2 levels (p&#x2009;&lt;&#x2009;0.01). However, only gender was shown to significantly influence sNfL changes with time (p&#xa0;=&#xa0;0.003).</AbstractText><AbstractText Label="CONCLUSIONS">In this study, sNfL levels increased with time in ALS patients and there was no difference between subjects already treated by Riluzole and those treated after sNfL1. Further studies with larger population samples and different sampling intervals are warranted to better determine the real potential of sNfL measurement as a tool to monitor treatment response in ALS.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. CNS Neuroscience &amp; Therapeutics published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esselin</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Explorations neurologiques et centre SLA, Univ Montpellier, CHU Gui de Chauliac, INM, INSERM, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De la Cruz</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Explorations neurologiques et centre SLA, Univ Montpellier, CHU Gui de Chauliac, INM, INSERM, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirtz</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>LBPC-PPC, Univ Montpellier, CHU Montpellier, INSERM, INM Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiers</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>LBPC-PPC, Univ Montpellier, CHU Montpellier, INSERM, INM Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alphandery</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Explorations neurologiques et centre SLA, Univ Montpellier, CHU Gui de Chauliac, INM, INSERM, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baudesson</LastName><ForeName>L&#xe9;andra</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Explorations neurologiques et centre SLA, Univ Montpellier, CHU Gui de Chauliac, INM, INSERM, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taieb</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Explorations neurologiques et centre SLA, Univ Montpellier, CHU Gui de Chauliac, INM, INSERM, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camu</LastName><ForeName>William</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-1287-7355</Identifier><AffiliationInfo><Affiliation>Explorations neurologiques et centre SLA, Univ Montpellier, CHU Gui de Chauliac, INM, INSERM, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>LBPC-PPC, Univ Montpellier, CHU Montpellier, INSERM, INM Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>CNS Neurosci Ther</MedlineTA><NlmUniqueID>101473265</NlmUniqueID><ISSNLinking>1755-5930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="Y">Riluzole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">Riluzole</Keyword><Keyword MajorTopicYN="N">Simoa</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>10</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35751632</ArticleId><ArticleId IdType="pmc">PMC9437233</ArticleId><ArticleId IdType="doi">10.1111/cns.13894</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27:1918&#x2010;1929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Silani V, Otto M. Neurochemical biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019;32:747&#x2010;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">31403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:251&#x2010;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437330</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Bonetto V, Sorar&#xf9; G, et al. Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Mol Neurodegener. 2020;15:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7559190</ArticleId><ArticleId IdType="pubmed">33059698</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchiano V, Mastrangelo A, Zenesini C, et al. Plasma and CSF neurofilament light chain in amyotrophic lateral sclerosis: a cross&#x2010;sectional and longitudinal study. Front Aging Neurosci. 2021;13:753242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8569186</ArticleId><ArticleId IdType="pubmed">34744694</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1&#x2010;2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2010;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Alberg L, Cullen NC, et al. NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol. 2019;266:2129&#x2010;2136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687695</ArticleId><ArticleId IdType="pubmed">31123861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald&#x2010;Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2010;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:157&#x2010;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130&#x2010;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59&#x2010;e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of Riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330:585&#x2010;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose&#x2010;ranging study of Riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/Riluzole study group II. Lancet. 1996;347:1425&#x2010;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie house diagnostic criteria: a population&#x2010;based study. Arch Neurol. 2000;57:1171&#x2010;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">10927797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS&#x2010;R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265&#x2010;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Jimenez CR, Johnson MH, Killestein J, Krasulova E, Kuhle J, Magnone MC, Petzold A, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Deisenhammer F, Giovannoni G, Hemmer B Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int 2011;2011:246412, 1, 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195993</ArticleId><ArticleId IdType="pubmed">22096631</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Kan CW, Campbell TG, et al. Single&#x2010;molecule enzyme&#x2010;linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28:595&#x2010;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919230</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Schuster J, Dreyhaupt J, et al. Effect of high&#x2010;caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020;91:1007&#x2010;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">32788256</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>